 Kalie Tommerdahl
Concepts (138)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetic Nephropathies | 10 | 2024 | 294 | 3.530 |
Why?
| | Diabetes Mellitus, Type 2 | 12 | 2025 | 2534 | 2.300 |
Why?
| | Diabetes Mellitus, Type 1 | 16 | 2026 | 3717 | 1.890 |
Why?
| | Metformin | 2 | 2023 | 331 | 1.140 |
Why?
| | Insulin Resistance | 5 | 2024 | 1211 | 1.080 |
Why?
| | Albuminuria | 2 | 2024 | 185 | 0.950 |
Why?
| | Hypoglycemic Agents | 6 | 2026 | 1294 | 0.860 |
Why?
| | Prediabetic State | 2 | 2024 | 253 | 0.690 |
Why?
| | Cystic Fibrosis | 2 | 2020 | 1114 | 0.650 |
Why?
| | Kidney | 8 | 2024 | 1475 | 0.640 |
Why?
| | Fructosamine | 1 | 2019 | 15 | 0.640 |
Why?
| | Deoxyglucose | 1 | 2019 | 53 | 0.630 |
Why?
| | Glucose Tolerance Test | 1 | 2020 | 366 | 0.610 |
Why?
| | Serum Albumin | 1 | 2019 | 150 | 0.600 |
Why?
| | Glomerular Filtration Rate | 6 | 2025 | 746 | 0.570 |
Why?
| | Adolescent | 17 | 2025 | 21574 | 0.500 |
Why?
| | Glucosides | 2 | 2025 | 44 | 0.420 |
Why?
| | Benzhydryl Compounds | 2 | 2025 | 73 | 0.410 |
Why?
| | Diabetes Mellitus | 1 | 2020 | 1041 | 0.370 |
Why?
| | Humans | 31 | 2026 | 137782 | 0.320 |
Why?
| | Insulin | 5 | 2026 | 2411 | 0.290 |
Why?
| | Child | 9 | 2025 | 21989 | 0.250 |
Why?
| | Creatinine | 3 | 2022 | 499 | 0.230 |
Why?
| | Young Adult | 10 | 2025 | 13240 | 0.220 |
Why?
| | Insulin Infusion Systems | 2 | 2026 | 396 | 0.220 |
Why?
| | Obesity, Abdominal | 1 | 2024 | 48 | 0.210 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2024 | 128 | 0.210 |
Why?
| | Body Composition | 2 | 2025 | 684 | 0.210 |
Why?
| | Diabetic Ketoacidosis | 2 | 2025 | 201 | 0.200 |
Why?
| | Hyperoxia | 1 | 2024 | 90 | 0.200 |
Why?
| | Mitochondria, Muscle | 1 | 2024 | 116 | 0.200 |
Why?
| | Receptors, Prolactin | 2 | 2012 | 7 | 0.190 |
Why?
| | Sex Characteristics | 2 | 2025 | 763 | 0.190 |
Why?
| | Glycoproteins | 1 | 2024 | 342 | 0.190 |
Why?
| | Obesity | 3 | 2025 | 2993 | 0.180 |
Why?
| | Adiposity | 2 | 2024 | 518 | 0.180 |
Why?
| | Bone Density | 1 | 2025 | 489 | 0.170 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 1 | 2021 | 82 | 0.170 |
Why?
| | Cardiovascular Diseases | 2 | 2024 | 2111 | 0.170 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2022 | 135 | 0.170 |
Why?
| | Male | 14 | 2025 | 67906 | 0.170 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 1 | 2024 | 262 | 0.170 |
Why?
| | Diabetic Neuropathies | 1 | 2021 | 94 | 0.160 |
Why?
| | Female | 15 | 2025 | 73465 | 0.160 |
Why?
| | Transcriptional Activation | 2 | 2012 | 378 | 0.160 |
Why?
| | Pulse Wave Analysis | 1 | 2021 | 274 | 0.160 |
Why?
| | Oxygen | 2 | 2024 | 938 | 0.160 |
Why?
| | Glycation End Products, Advanced | 1 | 2019 | 82 | 0.150 |
Why?
| | Diabetic Retinopathy | 1 | 2021 | 189 | 0.150 |
Why?
| | Respiratory Function Tests | 1 | 2020 | 601 | 0.150 |
Why?
| | Biomarkers | 3 | 2024 | 4154 | 0.140 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2024 | 617 | 0.140 |
Why?
| | Clinical Trials as Topic | 1 | 2022 | 1052 | 0.130 |
Why?
| | Risk Factors | 2 | 2021 | 10407 | 0.130 |
Why?
| | Cognition | 1 | 2024 | 1157 | 0.120 |
Why?
| | Phenotype | 2 | 2022 | 3196 | 0.120 |
Why?
| | Hemodynamics | 3 | 2024 | 1113 | 0.100 |
Why?
| | Hypoxia | 1 | 2020 | 1112 | 0.100 |
Why?
| | Brain | 1 | 2025 | 2677 | 0.100 |
Why?
| | Chitinase-3-Like Protein 1 | 2 | 2022 | 19 | 0.100 |
Why?
| | HMGN2 Protein | 1 | 2011 | 3 | 0.090 |
Why?
| | STAT5 Transcription Factor | 1 | 2011 | 57 | 0.090 |
Why?
| | Estrogen Receptor alpha | 1 | 2012 | 145 | 0.090 |
Why?
| | Mass Screening | 1 | 2019 | 1288 | 0.090 |
Why?
| | Receptors, Progesterone | 1 | 2012 | 350 | 0.080 |
Why?
| | Cross-Sectional Studies | 3 | 2025 | 5478 | 0.080 |
Why?
| | Tumor Suppressor Proteins | 1 | 2011 | 327 | 0.080 |
Why?
| | Cell Nucleus | 1 | 2011 | 620 | 0.070 |
Why?
| | Adult | 6 | 2025 | 38023 | 0.070 |
Why?
| | Case-Control Studies | 2 | 2025 | 3569 | 0.070 |
Why?
| | Transcription, Genetic | 1 | 2011 | 1457 | 0.060 |
Why?
| | Citric Acid Cycle | 1 | 2024 | 57 | 0.060 |
Why?
| | Gray Matter | 1 | 2025 | 80 | 0.060 |
Why?
| | Absorptiometry, Photon | 1 | 2025 | 259 | 0.050 |
Why?
| | Blood Glucose | 2 | 2025 | 2190 | 0.050 |
Why?
| | Mitochondrial Diseases | 1 | 2024 | 91 | 0.050 |
Why?
| | Age of Onset | 1 | 2025 | 520 | 0.050 |
Why?
| | Cysts | 1 | 2024 | 113 | 0.050 |
Why?
| | Glycolysis | 1 | 2024 | 321 | 0.050 |
Why?
| | Threonine | 1 | 2022 | 47 | 0.050 |
Why?
| | Histidine | 1 | 2022 | 64 | 0.050 |
Why?
| | Lipocalin-2 | 1 | 2022 | 79 | 0.050 |
Why?
| | Chemokine CCL2 | 1 | 2022 | 115 | 0.050 |
Why?
| | Lipoproteins | 1 | 2022 | 168 | 0.050 |
Why?
| | Leucine | 1 | 2022 | 111 | 0.050 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2024 | 611 | 0.050 |
Why?
| | Albumins | 1 | 2022 | 114 | 0.050 |
Why?
| | Prognosis | 2 | 2025 | 4039 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2024 | 1060 | 0.040 |
Why?
| | p-Aminohippuric Acid | 1 | 2020 | 6 | 0.040 |
Why?
| | Tryptophan | 1 | 2022 | 183 | 0.040 |
Why?
| | Interleukin-18 | 1 | 2022 | 236 | 0.040 |
Why?
| | Iohexol | 1 | 2020 | 23 | 0.040 |
Why?
| | Furosemide | 1 | 2020 | 37 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2025 | 1997 | 0.040 |
Why?
| | Triglycerides | 1 | 2022 | 524 | 0.040 |
Why?
| | Breast Neoplasms | 1 | 2012 | 2253 | 0.040 |
Why?
| | Glucose Clamp Technique | 1 | 2020 | 195 | 0.040 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2012 | 327 | 0.040 |
Why?
| | Neuropsychological Tests | 1 | 2024 | 1025 | 0.040 |
Why?
| | Sex Factors | 1 | 2025 | 2077 | 0.040 |
Why?
| | Cognitive Dysfunction | 1 | 2024 | 383 | 0.040 |
Why?
| | Pilot Projects | 1 | 2024 | 1713 | 0.040 |
Why?
| | Amino Acids | 1 | 2022 | 497 | 0.040 |
Why?
| | Diabetes Complications | 1 | 2020 | 227 | 0.040 |
Why?
| | Energy Metabolism | 1 | 2024 | 922 | 0.040 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2022 | 641 | 0.030 |
Why?
| | Precision Medicine | 1 | 2020 | 433 | 0.030 |
Why?
| | Body Mass Index | 1 | 2025 | 2390 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2012 | 1396 | 0.030 |
Why?
| | Disease Management | 1 | 2020 | 629 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2025 | 5136 | 0.030 |
Why?
| | Muscle, Skeletal | 1 | 2024 | 1724 | 0.030 |
Why?
| | Genes, Neoplasm | 1 | 2012 | 22 | 0.020 |
Why?
| | Tissue Array Analysis | 1 | 2012 | 57 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2025 | 3577 | 0.020 |
Why?
| | Prolactin | 1 | 2012 | 96 | 0.020 |
Why?
| | Exercise | 1 | 2024 | 2061 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2012 | 955 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2011 | 327 | 0.020 |
Why?
| | Down-Regulation | 1 | 2012 | 657 | 0.020 |
Why?
| | Protein Transport | 1 | 2011 | 445 | 0.020 |
Why?
| | Up-Regulation | 1 | 2012 | 843 | 0.020 |
Why?
| | Neoplasm Proteins | 1 | 2012 | 434 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2011 | 861 | 0.020 |
Why?
| | Phosphorylation | 1 | 2012 | 1759 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2011 | 2139 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2011 | 2900 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2011 | 1251 | 0.020 |
Why?
| | United States | 1 | 2024 | 14870 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2012 | 1276 | 0.010 |
Why?
| | Protein Binding | 1 | 2011 | 2224 | 0.010 |
Why?
| | Disease Progression | 1 | 2012 | 2760 | 0.010 |
Why?
| | Models, Biological | 1 | 2011 | 1783 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2011 | 3415 | 0.010 |
Why?
| | Middle Aged | 1 | 2024 | 33554 | 0.010 |
Why?
| | Mutation | 1 | 2012 | 3959 | 0.010 |
Why?
| | Animals | 1 | 2020 | 36951 | 0.010 |
Why?
|
|
Tommerdahl's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|